Asciminib Shows Activity in Heavily Pretreated Patients with CML
It binds to the myristoyl pocket, a previously unexploited feature of ABL1 and ABL2 kinases
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1636 results
EMA Recommends Extension of Therapeutic Indications for Apalutamide
New indication concerns the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy
Professor Pierre Alberto: serving ESMO as outstanding oncologist, educator and mentor
ESMO is sad to learn of the death of Professor Pierre Alberto, a wise and thoughtful oncologist whose clinical innovations and educational initiatives had a lasting impact.
HER2CLIMB and DESTINY-Breast01 Findings in Heavily Pretreated HER2-positive MBC
Results from the studies with tucatinib, trastuzumab deruxtecan in patients with metastatic breast cancer
BL-8040, Pembrolizumab and Chemotherapy Deliver Promising Disease Control in Patients with Metastatic Pancreatic Adenocarcinoma
CXCR4 antagonist, BL-8040 modifies the tumour microenvironment
The QuIP Study Attempts to Harmonise the Use of TMB Panels
TMB is actively being studied as a predictive biomarker for identifying patients who might benefit from immunotherapy but the issue of variability between assays has been raised
Sitravatinib Plus Tislelizumab Show Promise in Platinum-Resistant Advanced Ovarian Cancer
Novel combination of sitravatinib and tislelizumab shows manageable safety and promising activity in phase Ib study
First-Line Combination Treatment with Durvalumab Plus Platinum and Etoposide Has Manageable Safety in ES-SCLC
Results from analyses of safety, pharmacokinetics and immunogenecity in the CASPIAN trial
First-line Nivolumab Plus Chemotherapy Did Not Meet the Primary Endpoint of Overall Survival in Non-Squamous NSCLC
Results of the CheckMate 227 - part 2 final analysis
Early Introduction of Corticosteroids May Alter the Efficacy of Immune Checkpoint Inhibitors
Two studies describe impact of the initiation of steroids early during the course of immune checkpoint inhibition on patient outcome
First-line Nivolumab Plus Ipilimumab is Safe and Provides Encouraging Survival in Patients with Advanced NSCLC and Co-Morbidity or Poor Performance Status
Nivolumab plus ipilimumab is effective regardless of PD-L1 expression levels in advanced NSCLC
Pembrolizumab May Be Considered as a First-Line Treatment Option in Non-Squamous NSCLC Even in the Presence of KRAS Mutations
Efficacy of pembrolizumab alone or combined with chemotherapy is solid regardless of KRAS mutations in non-squamous non-small cell lung cancer